DOI 10.1080/07853890.2025.2526109
Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction.
Аннотация
BACKGROUND
Adenocarcinoma of the esophagogastric junction (AEG) is a common upper gastrointestinal malignancy.
AIM: This study investigates the impact of long non-coding RNA NORAD on the short-term efficacy of oxaliplatin-based neoadjuvant chemotherapy in AEG.
METHODS
Patients with advanced AEG received oxaliplatin-based neoadjuvant chemotherapy. Oxaliplatin- sensitive (PDCs) and oxaliplatin-resistant (PDC-Rs) primary tumor cell lines were established, and NORAD- knockdown PDC-R cells (shNORAD PDC-R) were generated. NORAD expression in pretreatment tumor tissues was measured by qRT-PCR. The half-maximal inhibitory concentration (IC50) was determined for all cell lines.
RESULTS
NORAD expression correlated with Lauren classification. The low-expression group showed higher overall response rate, tumor regression grade, and pathological remission rate after chemotherapy. Pretreatment NORAD expression was an independent predictor of 3-year disease-free survival (DFS). IC50 values for PDC, PDC-R, and shNORAD PDC-R cells were 2.32, 21.41, and 3.82 μg/mL oxaliplatin, respectively.
CONCLUSIONS
High pretreatment NORAD expression is an independent risk factor for poor response to neoadjuvant chemotherapy. Downregulating NORAD restores oxaliplatin sensitivity in resistant cells.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.